Pathos AI vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage AI company raised $365M Series D at $1.6B for world's largest multimodal oncology AI; Novo Nordisk partnership; $467M total;
About
Pathos AI is a clinical-stage AI company building the world's largest multimodal oncology AI platform, combining pathology imaging, genomics, clinical records, and treatment outcome data to power precision cancer care. Founded by oncologists, pathologists, and AI researchers, Pathos has assembled a dataset at a scale that gives its models a meaningful edge: by ingesting vast quantities of multimodal cancer data, its platform can predict treatment responses, identify biomarkers, and guide therapy selection with a level of accuracy that single-modality systems cannot match.\n\nThe platform serves oncologists and cancer centers by providing AI-augmented pathology reads, treatment outcome predictions, and clinical trial matching. Pathos's AI can analyze whole-slide pathology images in combination with molecular and clinical data to generate insights that inform diagnosis and treatment decisions. The company has also built partnerships with pharmaceutical companies — including Novo Nordisk and Prelude Therapeutics — to use its platform for drug development and clinical trial design, adding a biopharma revenue stream alongside its clinical business.\n\nPathos raised $365M in a Series D round at a $1.6B valuation, bringing total funding to $467M. The Series D was one of the largest oncology AI fundraises in history and included backing from top-tier life sciences investors. The Novo Nordisk and Prelude partnerships validate the platform's scientific depth and its utility across both clinical care and drug development. As of 2025–2026, Pathos is advancing toward direct clinical deployment and regulatory submissions, positioning itself as a core infrastructure layer for the future of AI-guided cancer treatment.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.